PTPRC and neoplasm: Recently, Huang et al. [20] demonstrated in in vivo studies that aptCTLA-4 treatment significantly increases the number of tumor-infiltrating lymphocytes (CD45+) and the percentage of cytotoxic T lymphocytes (CTLs) (CD45+ and CD8+), as observed in flow cytometry analyses.